New drug duo aims to shrink lung tumors before surgery
NCT ID NCT07281209
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs (SHR-A1811 and adebelimumab) given before surgery to people with early-stage non-small cell lung cancer that has a specific genetic change (HER2 alteration). The goal is to see if the combination can shrink or eliminate the tumor before it is removed. About 40 participants will take part in this phase 2 trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can extended poziotinib use keep cancer in check?
- Can zapping tumors before surgery boost lung cancer treatment?
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?